BTK and diffuse large B-cell lymphoma: In 2018, our group reported the first new protein degrader P13I (Sun Y. H. et al., 2018; 12, Figure 5), which can be used in a variety of B cell malignancies (mantle cell lymphoma, diffuse large B cell lymphoma, multiple myeloma) with drug concentration less than 10 nM to efficiently degrade BTK protein.